KromaTiD Announces Third U.S. Patent and New Proprietary Capabilities

KromaTiD Announces Third U.S. Patent and New Proprietary Capabilities Fort Collins, Colorado September 21, 2015:  With the issuance of its third U.S. patent (#9,090,935 B2), KromaTiD is pleased to announce an expansion of its full genome screening platform to include a new set of unique methods for understanding the structure of novel disease causing mutations.

Houston…The Samples Have Landed!

Houston…The Samples Have Landed! NASA Twins Study investigator Susan Bailey, KromaTiD co-founder and Colorado State University Professor, and her team of researchers, Miles McKenna and Lynn Taylor, recently received their first samples from the International Space Station (ISS).  The samples are from NASA astronaut Scott Kelly, who is on the ride of his life; the […]

KromaTiD Appoints tebu-bio as European Distributor

KromaTiD Appoints Tebu-Bio as European Distributor FORT COLLINS, CO (February 9, 2015) – KromaTiD, Inc. is pleased to announce that is partnering with tebu-bio for distribution of its proprietary dGH™ and Pinpoint FISH™ products and services throughout Europe. Headquartered in France, tebu-bio has offices in nine European countries and specializes in supplying innovative life science products and […]

KromaTiD Launches Genome Screening and Discovery Services

FORT COLLINS, CO (October 18th, 2014) – KromaTiD, Inc. is pleased to announce the launch of its directional Genomic HybridizationTM (dGHTM) screening services at the American Society of Human Genomics in San Diego October 18-22. Read more

KromaTiD Hires Alex D. Vodenlich as new CEO

FORT COLLINS, CO (February 3, 2014) – KromaTiD, Inc. announces that Alex D. Vodenlich of Madison, WI, will be joining as its chief executive officer. Mr. Vodenlich is an executive with over twenty years experience in the life science industry. He is the former President and CEO of Gentel Biosciences, Inc., a provider of multiplex immunoassay technologies. Read more